Banco Bilbao Vizcaya Argentaria, S.A. Trevi Therapeutics, Inc. Transaction History
Banco Bilbao Vizcaya Argentaria, S.A.
- $10.9 Billion
- Q2 2025
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
159Shares Held
107MCall Options Held
1.15MPut Options Held
335K-
Nea Management Company, LLC Timonium, MD13.2MShares$96.9 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$75.2 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$62.5 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$39 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.49MShares$32.9 Million5.2% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $428M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...